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Background and Aim: We have previously shown that CD4+CD28null 
(CD28null) T cells, a unique T lymphocyte subset with pro-inflammatory and 
cell-lytic phenotype that are apoptosis resistant, expand in patients with 
myocardial infarction (MI). MI patients harbouring high CD28null T cell 
numbers have increased risk of recurrent severe acute coronary events and 
unfavourable prognosis. The mechanisms that govern CD28null T cell 
expansion in MI remain elusive. The pro-inflammatory cytokine tumour 
necrosis factor-α (TNF-α) has been implicated in CD28null T cell expansion in 
rheumatoid arthritis. We investigated the effect of inflammatory and 
homeostatic cytokines on CD28null T cells in MI patients. 
Methods: Freshly isolated cells from MI patients were treated with 
recombinant human cytokines (TNF-α, IL-1β, IL-6, IL-7 and IL-15) and the 
number, activation, function and proliferation of CD28null T cells were 
analysed. 
Results: We found that pro-inflammatory cytokines TNF-α, IL-1β and IL-6 did 
not have any effect on CD28null T cell number. Strikingly, homeostatic 
cytokines IL-7 and IL-15 triggered expansion of CD28null T cells from MI 
patients, which was mediated by cell proliferation. Moreover, we demonstrate 
for the first time that IL-7 and IL-15 activate CD28null T cells and increase their 
cytotoxic function. 
Conclusions: We showed that IL-7 and IL-15 and not pro-inflammatory 
cytokines are the main drivers of CD28null T cell expansion in MI patients. Our 
novel findings suggest that anti-inflammatory drugs targeting TNF-α, IL-1 and 
IL-6 may fail to control CD28null T cell expansion in MI patients and that 
therapeutic strategies targeting alternative cytokines (IL-7, IL-15) may be 
beneficial. 
 
 
